Literature DB >> 3489870

Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent.

A J Farré, M Colombo, M Fort, B Gutiérrez, L Rodríguez, R Roser.   

Abstract

Droxicam showed high antiinflammatory activity in carrageenin-induced edema in rat. At doses of 0.25 and 0.5 mg/kg, droxicam was as active as piroxicam and more active than phenylbutazone given at 2.5 and 5 mg/kg. Against nystatin-induced edema, droxicam (ED50, p.o., 5, 6, 7, 8 h: 7.5, 12.9, 4.8, 8.4 mg/kg) was 4-11 times more active than phenylbutazone and more than 12 times more active than isoxicam. In cotton pellet-induced granuloma in rats, title compound was as active as suprofen. In U.V. light-induced erythema in guinea pigs, droxicam (ED50, p.o., 1, 2, 3, 4 h: 0.51, 0.94, 1.56, 4.88 mg/kg) was 5-9 times more active than phenylbutazone. At doses of 0.1, 0.33 and 1.0 mg/kg/day, droxicam, similar to piroxicam, showed good antiarthritic activity in rats injected with Mycobacterium butyricum against primary and secondary lesions. Droxicam demonstrated strong analgesic activity in protecting against writhings: induced by phenylbenzoquinone in mice: ED50: droxicam = 5.3, phenylbutazone = 61.5, acetylsalicylic acid = 90.7, dipyrone = 83.6, isoxicam = 88.3 mg/kg, p.o.; induced by acetylcholine bromide in mice: ED50: droxicam = 1.1, phenylbutazone = 32.1, acetylsalicylic acid = 32.2, isoxicam = 32.7 mg/kg, p.o.; induced by acetic acid in rat: ED50: droxicam = 0.94, acetylsalicylic acid = 8.72, isoxicam = 4.70 mg/kg, p.o. Antipyretic activity of title compound was demonstrated in rats with pyresis induced by brewer's yeast, being 4-13 times more active than dipyrone. In pyresis induced by Salmonella typhi, droxicam was more active than acetylsalicylic acid and 4-aminoantipyrine at all times and doses. In a study of protection against diarrhea induced by castor oil in rats, droxicam and piroxicam showed equal activity (ED50 = 0.081 and 0.079 mg/kg, p.o., respectively) and were 3.9 and 15.6 times more active than isoxicam and phenylbutazone, respectively. Droxicam significantly inhibited peritoneal capillary permeability in mice at a dose of 5 mg/kg, p.o., while isoxicam and phenylbutazone required 100 and 200 mg/kg, p.o., respectively. Droxicam did not exhibit uricosuric activity in rats. It did not show cardiovascular or respiratory effects in anesthetized cats, nor modify their response to administration of acetylcholine, norepinephrine and histamine. In the Irwin's test, droxicam did not alter rat behavior (80 mg/kg, i.p.) nor that of mice (160 mg/kg, p.o.). Induction of gastrointestinal injuries in rats by droxicam was 10 times less than by piroxicam (UD50: droxicam, 57 mg/kg, p.o.; piroxicam, 5.6 mg/kg, p.o.). The potentiation of gastric injuries induced by stress through cold in rats was also studied.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489870

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  6 in total

1.  Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers.

Authors:  L Martinez; J Sanchez; R Roser; J Garcia-Barbal; R Sagarra; A Bartlett
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

2.  A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics.

Authors:  M T Maya; J P Pais; J Ruas Da Silva; J A Morais
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

3.  Synthesis and pharmacological evaluation of pyrazolopyrimidopyrimidine derivatives: anti-inflammatory agents with gastroprotective effect in rats.

Authors:  Amine Karoui; Fatma Allouche; Monia Deghrigue; Asma Agrebi; Abderrahman Bouraoui; Fakher Chabchoub
Journal:  Med Chem Res       Date:  2013-09-04       Impact factor: 1.965

4.  Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam.

Authors:  T J Carty; A Marfat; P F Moore; F C Falkner; T M Twomey; A Weissman
Journal:  Agents Actions       Date:  1993-07

5.  Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.

Authors:  Shu Xu; Daniel J Hermanson; Surajit Banerjee; Kebreab Ghebreselasie; Gina M Clayton; R Michael Garavito; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2014-01-14       Impact factor: 5.157

6.  Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration.

Authors:  A Bartlett; A Costa; L Martinez; R Roser; R Sagarra; J Sanchez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.